A Portfolio of
Novel Targeted Antibodies

A Portfolio of
Novel Targeted Antibodies

pipeline

Following these lead programs, Resonant has generated an expanding collection of novel targeted antibodies.
Our team has identified and is developing these assets as naked antibodies, antibody-drug conjugates, bi-specifics and other therapeutic formats.

© 2017 - 2022 Resonant Therapeutics